Evaluation of Elevated Liver Enzymes

Clinics in Liver Disease

Volumn 16, Issue 2, 2012, Pages 183-198

  Lee, Tae Hoon ^a   Kim, W Ray ^b   Poterucha, John J ^b  

^a MARSHALL UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Alkaline phosphatase; Aminotransferase; Diagnostic algorithm; Gamma glutamyl transferase; Liver enzymes

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CERULOPLASMIN; GAMMA GLUTAMYLTRANSFERASE; HALOTHANE; INHALATION ANESTHETIC AGENT;

ALCOHOL LIVER DISEASE; ALLERGIC REACTION; ALPHA ANTITRYPSIN DEFICIENCY; AMYLOIDOSIS; AUTOIMMUNE HEPATITIS; BLOOD TRANSFUSION; BODY MASS; BUDD CHIARI SYNDROME; CERULOPLASMIN BLOOD LEVEL; CHOLESTATIC HEPATITIS; CHROMATOGRAPHY; COLORIMETRY; DELTA AGENT HEPATITIS; DRUG INDUCED DISEASE; ENZYME ACTIVITY; FLUOROMETRY; HEART DISEASE; HELLP SYNDROME; HEMOCHROMATOSIS; HEPATITIS A; HEPATITIS B; HEPATITIS C; HEPATITIS E; HUMAN; HYPERBILIRUBINEMIA; HYPERTRANSAMINASEMIA; LIVER BIOPSY; LIVER INJURY; LIVER ISCHEMIA; LIVER TOXICITY; MYOPATHY; NONALCOHOLIC FATTY LIVER; ORGAN TRANSPLANTATION; POSTOPERATIVE PERIOD; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; REVIEW; SARCOIDOSIS; SIDE EFFECT; SPECTROPHOTOMETRY; THYROID DISEASE; WILSON DISEASE;

ALANINE TRANSAMINASE; ALGORITHMS; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASES; CLINICAL ENZYME TESTS; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; LIVER DISEASES; POSTOPERATIVE PERIOD;

EID: 84860316014     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2012.03.006     Document Type: Review

References (65)

1. Pratt D.S., Kaplan M.M. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med 2000, 342:1266-1271.
2. Kim H.C., Nam C.M., Jee S.H., et al. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. BMJ 2004, 328:983.
3. Lee T.H., Kim W.R., Benson J.T., et al. Serum aminotransferase activity and mortality risk in a United States community. Hepatology 2008, 47:880-887.
4. Haber M.M., West A.B., Haber A.D., et al. Relationship of aminotransferases to liver histological status in chronic hepatitis C. Am J Gastroenterol 1995, 90:1250-1257.
5. Sanyal A.J. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002, 123:1705-1725.
6. Schiff's diseases of the liver 2007, Lippincott Williams & Wilkins, Philadelphia. 10th edition. E.R. Schiff, M.F. Sorrell, W.C. Maddrey (Eds.).
7. Green R., Flamm S. AGA technical review on the evaluation of liver chemistry tests. Gastroenterology 2002, 123:1367-1384.
8. Yang R.Z., Blaileanu G., Hansen B.C., et al. cDNA cloning, genomic structure, chromosomal mapping, and functional expression of a novel human alanine aminotransferase. Genomics 2002, 79:445-450.
9. Wroblewski F. The clinical significance of transaminase activities of serum. Am J Med 1959, 27:911-923.
10. Prati D., Taioli E., Zanella A., et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002, 137:1-10.
11. Piton A., Poynard T., Imbert-Bismut F., et al. Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. MULTIVIRC Group. Hepatology 1998, 27:1213-1219.
12. Friedman L.S., Dienstag J.L., Watkins E., et al. Evaluation of blood donors with elevated serum alanine aminotransferase levels. Ann Intern Med 1987, 107:137-144.
13. Lazo M., Selvin E., Clark J.M. Brief communication: clinical implications of short-term variability in liver function test results. Ann Intern Med 2008, 148:348-352.
14. Cordoba J., O'Riordan K., Dupuis J., et al. Diurnal variation of serum alanine transaminase activity in chronic liver disease. Hepatology 1998, 28:1724-1725.
15. Ellis G., Goldberg D.M., Spooner R.J., et al. Serum enzyme tests in diseases of the liver and biliary tree. Am J Clin Pathol 1978, 70:248-258.
16. Browning J.D., Szczepaniak L.S., Dobbins R., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004, 40:1387-1395.
17. Bacon B.R., Farahvash M.J., Janney C.G., et al. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994, 107:1103-1109.
18. Wong V.W., Vergniol J., Wong G.L., et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010, 51:454-462.
19. Angulo P., Hui J.M., Marchesini G., et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007, 45:846-854.
20. Cohen J.A., Kaplan M.M. The SGOT/SGPT ratio-an indicator of alcoholic liver disease. Dig Dis Sci 1979, 24:835-838.
21. Nyblom H., Berggren U., Balldin J., et al. High AST/ALT ratio may indicate advanced alcoholic liver disease rather than heavy drinking. Alcohol Alcohol 2004, 39:336-339.
22. Regier D.A., Farmer M.E., Rae D.S., et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990, 264:2511-2518.
23. Sleisenger and Fordtran's gastrointestinal and liver disease 2006, Saunders, Philadelphia. 8th edition. M. Feldman, L.S. Friedman, L.J. Brandt (Eds.).
24. Verma S., Kaplowitz N. Diagnosis, management and prevention of drug-induced liver injury. Gut 2009, 58:1555-1564.
25. Ramrakhiani S., Brunt E.M., Bacon B.R. Possible cholestatic injury from ranitidine with a review of the literature. Am J Gastroenterol 1998, 93:822-826.
26. Yokoyama M., Yokoyama A., Mori S., et al. Inducible histamine protects mice from P. acnes-primed and LPS-induced hepatitis through H2-receptor stimulation. Gastroenterology 2004, 127:892-902.
27. Ramachandran R., Kakar S. Histological patterns in drug-induced liver disease. J Clin Pathol 2009, 62:481-492.
28. Kao H.W., Ashcavai M., Redeker A.G. The persistence of hepatitis A IgM antibody after acute clinical hepatitis A. Hepatology 1984, 4:933-936.
29. Zignego A.L., Deny P., Feray C., et al. Amplification of hepatitis delta virus RNA sequences by polymerase chain reaction: a tool for viral detection and cloning. Mol Cell Probes 1990, 4:43-51.
30. Madejon A., Castillo I., Bartolome J., et al. Detection of HDV-RNA by PCR in serum of patients with chronic HDV infection. J Hepatol 1990, 11:381-384.
31. Pawlotsky J.M. Use and interpretation of virological tests for hepatitis C. Hepatology 2002, 36:S65-S73.
32. Mast E.E., Alter M.J., Holland P.V., et al. Evaluation of assays for antibody to hepatitis E virus by a serum panel. Hepatitis E Virus Antibody Serum Panel Evaluation Group. Hepatology 1998, 27:857-861.
33. Markin R.S. Manifestations of Epstein-Barr virus-associated disorders in liver. Liver 1994, 14:1-13.
34. Goodgame R.W. Gastrointestinal cytomegalovirus disease. Ann Intern Med 1993, 119:924-935.
35. Sharma S., Mosunjac M. Herpes simplex hepatitis in adults: a search for muco-cutaneous clues. J Clin Gastroenterol 2004, 38:697-704.
36. Adams P.C., Reboussin D.M., Barton J.C., et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med 2005, 352:1769-1778.
37. Bacon B.R., Adams P.C., Kowdley K.V., et al. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011, 54:328-343.
38. Roberts E.A., Schilsky M.L. Diagnosis and treatment of Wilson disease: an update. Hepatology 2008, 47:2089-2111.
39. de Serres F.J., Blanco I., Fernandez-Bustillo E. Genetic epidemiology of alpha-1 antitrypsin deficiency in North America and Australia/New Zealand: Australia, Canada, New Zealand and the United States of America. Clin Genet 2003, 64:382-397.
40. Manns M.P., Vogel A. Autoimmune hepatitis, from mechanisms to therapy. Hepatology 2006, 43:S132-S144.
41. Alvarez F., Berg P.A., Bianchi F.B., et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999, 31:929-938.
42. Kim W.R., Lindor K.D., Locke G.R., et al. Epidemiology and natural history of primary biliary cirrhosis in a US community. Gastroenterology 2000, 119:1631-1636.
43. Bambha K., Kim W.R., Talwalkar J., et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 2003, 125:1364-1369.
44. European Association for the Study of the Liver EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009, 51:237-267.
45. Czaja A.J. The variant forms of autoimmune hepatitis. Ann Intern Med 1996, 125:588-598.
46. Kumar S., DeLeve L.D., Kamath P.S., et al. Hepatic veno-occlusive disease (sinusoidal obstruction syndrome) after hematopoietic stem cell transplantation. Mayo Clin Proc 2003, 78:589-598.
47. Cassidy W.M., Reynolds T.B. Serum lactic dehydrogenase in the differential diagnosis of acute hepatocellular injury. J Clin Gastroenterol 1994, 19:118-121.
48. Olsson R.G., Lindgren A., Zettergren L. Liver involvement in Addison's disease. Am J Gastroenterol 1990, 85:435-438.
49. Miller K.K., Grinspoon S.K., Ciampa J., et al. Medical findings in outpatients with anorexia nervosa. Arch Intern Med 2005, 165:561-566.
50. Litin S.C., O'Brien J.F., Pruett S., et al. Macroenzyme as a cause of unexplained elevation of aspartate aminotransferase. Mayo Clin Proc 1987, 62:681-687.
51. Ruhl C.E., Everhart J.E. Elevated serum alanine aminotransferase and gamma-glutamyltransferase and mortality in the United States population. Gastroenterology 2009, 136:477-485.e11.
52. Schindhelm R.K., Dekker J.M., Nijpels G., et al. Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis 2007, 191:391-396.
53. Rosch T., Meining A., Fruhmorgen S., et al. A prospective comparison of the diagnostic accuracy of ERCP, MRCP, CT, and EUS in biliary strictures. Gastrointest Endosc 2002, 55:870-876.
54. Freeman M.L., Nelson D.B., Sherman S., et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med 1996, 335:909-918.
55. Hanje A.J., Patel T. Preoperative evaluation of patients with liver disease. Nat Clin Pract Gastroenterol Hepatol 2007, 4:266-276.
56. Gelman S. General anesthesia and hepatic circulation. Can J Physiol Pharmacol 1987, 65:1762-1779.
57. Cunningham A.J., Brull S.J. Laparoscopic cholecystectomy: anesthetic implications. Anesth Analg 1993, 76:1120-1133.
58. Kharasch E.D. Adverse drug reactions with halogenated anesthetics. Clin Pharmacol Ther 2008, 84:158-162.
59. Summary of the national Halothane Study. Possible association between halothane anesthesia and postoperative hepatic necrosis. JAMA 1966, 197:775-788.
60. Mikatti N.E., Healy T.E. Hepatic injury associated with halogenated anaesthetics: cross-sensitization and its clinical implications. Eur J Anaesthesiol 1997, 14:7-14.
61. Fudickar A., Bein B. Propofol infusion syndrome: update of clinical manifestation and pathophysiology. Minerva Anestesiol 2009, 75:339-344.
62. Gutelius B., Perz J.F., Parker M.M., et al. Multiple clusters of hepatitis virus infections associated with anesthesia for outpatient endoscopy procedures. Gastroenterology 2010, 139:163-170.
63. Dwyre D.M., Fernando L.P., Holland P.V. Hepatitis B, hepatitis C and HIV transfusion-transmitted infections in the 21st century. Vox Sang 2011, 100:92-98.
64. Eid A.J., Razonable R.R. New developments in the management of cytomegalovirus infection after solid organ transplantation. Drugs 2010, 70:965-981.
65. Kowdley K.V., Keeffe E.B. Hepatotoxicity of transplant immunosuppressive agents. Gastroenterol Clin North Am 1995, 24:991-1001.